SPFH1 Activators
SPFH1 activators are compounds that target and augment the activity of the SPFH1 protein, also known as stomatin. SPFH1 is a member of the SPFH domain/prohibitin family, which encompasses a group of membrane-associated proteins with a characteristic SPFH domain. This domain is implicated in various cellular processes, including membrane organization, ion channel regulation, and intracellular signaling. SPFH1 itself is noted for its presence in lipid raft domains within the plasma membrane and is believed to play a role in stabilizing membrane proteins and contributing to the formation of membrane microdomains. The activators of SPFH1 are therefore involved in modulating the functional state of SPFH1, potentially affecting the protein's capacity to interact with other membrane proteins or lipids and influence the structural integrity and signaling functions of the membrane domains where it resides.
The chemical structure of SPFH1 activators is diverse but tailored to interact specifically with the SPFH1 protein. These molecules typically possess functional groups that facilitate their integration into the membrane environment and allow them to engage directly with the SPFH1 protein. The activators may mimic natural ligands or substrates of SPFH1 or might interact allosterically to induce a conformational change that results in an upregulation of SPFH1 activity. This interaction can enhance the protein-protein or protein-lipid associations that SPFH1 mediates, thus potentially affecting the properties of the lipid rafts and related cellular functions. The activators' design often leverages knowledge of the SPFH1 protein structure, including the unique features of its SPFH domain, to optimize binding affinity and specificity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
myo-Inositol | 87-89-8 | sc-202714 sc-202714A sc-202714B sc-202714C | 100 g 250 g 1 kg 5 kg | $80.00 $151.00 $275.00 $837.00 | ||
As a precursor for the synthesis of inositol 1,4,5-trisphosphate (IP3) receptors, which SPFH1 is known to help degrade, an increase in inositol levels might lead to a rise in IP3 receptor synthesis, possibly demanding an upregulation of SPFH1 to manage the surplus receptors. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
By inhibiting HMG-CoA reductase like other statins, atorvastatin reduces cholesterol synthesis. This reduction might potentially stimulate an increase in SPFH1 expression to maintain cholesterol homeostasis. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin, another HMG-CoA reductase inhibitor, could potentially stimulate an increase in SPFH1 expression by altering cholesterol homeostasis due to reduced cholesterol synthesis. | ||||||
Pravastatin | 81093-37-0 | sc-222188 | 50 mg | $408.00 | 1 | |
Pravastatin, a statin agent in research, could potentially cause an upregulation of SPFH1 by inhibiting cholesterol synthesis, which in turn might necessitate a response from SPFH1 to maintain balance. | ||||||
Farnesol | 4602-84-0 | sc-204748 sc-204748A | 50 ml 100 ml | $281.00 $374.00 | 2 | |
Farnesol, an intermediate in the mevalonate pathway that leads to cholesterol production, could potentially stimulate an increase in SPFH1 expression by altering the levels of cholesterol synthesis intermediates. | ||||||
Squalene | 111-02-4 | sc-281155 sc-281155A sc-281155B | 10 ml 100 ml 500 ml | $49.00 $92.00 $215.00 | 1 | |
Squalene, another intermediate in cholesterol synthesis, might stimulate an increase in SPFH1 expression due to changes in the levels of intermediates in the cholesterol synthesis pathway. | ||||||
Geranylgeranylpyrophosphate triammonium salt | 6699-20-3 | sc-200849 | 200 µg | $122.00 | ||
Geranylgeranyl pyrophosphate, a product of the mevalonate pathway, might stimulate an increase in SPFH1 expression due to changes in the levels of downstream products of the mevalonate pathway. | ||||||